Sutro Biopharma (NASDAQ:STRO) just reported results for the second quarter of 2024.
- Sutro Biopharma reported earnings per share of -59 cents. This was above the analyst estimate for EPS of -79 cents.
- The company reported revenue of $25.71 million.
- This was 22.29% better than the analyst estimate for revenue of $21.02 million.